Biocause Pharma(SZ:000627) Xin Lang Cai Jing·2025-08-28 12:51Core Viewpoint - *ST Tianmao announced that it will be unable to disclose its 2025 semi-annual report on the scheduled date and is expected to miss the statutory deadline for disclosure [1] Group 1: Financial Reporting Issues - The company has not completed the preparation of its 2024 annual report and 2025 first-quarter report, leading to the inability to disclose the 2025 semi-annual report on August 29 [1] - The company's stock has been subjected to delisting risk warnings due to the failure to timely disclose the 2024 annual report and 2025 first-quarter report [1] Group 2: Potential Delisting - If the company fails to disclose more than half of the directors' assurance of the authenticity, accuracy, and completeness of the 2024 annual report within two months, the Shenzhen Stock Exchange may decide to terminate the company's stock listing [1] - The company has convened a shareholders' meeting to approve the voluntary termination of its listing and will submit the application to the Shenzhen Stock Exchange within fifteen trading days after the resolution [1]